A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Trial Title: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT ID: NCT05120349

Condition: Non-Small Cell Lung Cancer

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Osimertinib

Conditions: Keywords:
Osimertinib
Tagrisso
NSCLC
Non-small Cell Lung Cancer
Resectable
EGFRm Positive
Adjuvant
Stage IA2-IA3

Study type: Interventional

Study phase: Phase 3

Overall status: Active, not recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: Triple (Participant, Care Provider, Investigator)

Intervention:

Intervention type: Drug
Intervention name: Osimertinib
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
Arm group label: Osimertinib

Other name: AZD9291; TAGRISSO

Intervention type: Drug
Intervention name: Placebo
Description: Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
Arm group label: Placebo

Summary: This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Detailed description: This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R). Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.

Criteria for eligibility:
Criteria:
Inclusion Criteria 1. Male or female, at least ≥ 18 years. 2. NSCLC, of non-squamous histology. 3. Stage IA2 or IA3 disease, based on TNM8 classification. 4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection. 5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants. 6. World Health Organization performance status of 0 or 1. 7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation. 8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test. 9. Minimum life expectancy of > 6 months. 10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception. Exclusion Criteria 1. Mixed small cell and non-small cell cancer history. 2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection. 3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection. 4. History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence. 5. Any of the following cardiac criteria: - Mean resting QTcF interval > 470 ms, obtained from triplicate ECGs performed at screening. - Any abnormalities in rhythm, conduction, or morphology of resting ECG, - Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events. 6. History of interstitial lung disease. 7. Inadequate bone marrow reserve or organ function. 8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention. 9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs). 10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention. 11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Research Site

Address:
City: Anchorage
Zip: 99508
Country: United States

Facility:
Name: Research Site

Address:
City: Los Angeles
Zip: 90024
Country: United States

Facility:
Name: Research Site

Address:
City: Orange
Zip: 92868
Country: United States

Facility:
Name: Research Site

Address:
City: Grand Junction
Zip: 81501
Country: United States

Facility:
Name: Research Site

Address:
City: Newark
Zip: 19713
Country: United States

Facility:
Name: Research Site

Address:
City: Atlanta
Zip: 30322
Country: United States

Facility:
Name: Research Site

Address:
City: Chicago
Zip: 60612
Country: United States

Facility:
Name: Research Site

Address:
City: Frederick
Zip: 21702
Country: United States

Facility:
Name: Research Site

Address:
City: Morristown
Zip: 07960
Country: United States

Facility:
Name: Research Site

Address:
City: Flushing
Zip: 11355
Country: United States

Facility:
Name: Research Site

Address:
City: New York
Zip: 10032
Country: United States

Facility:
Name: Research Site

Address:
City: New York
Zip: 10065
Country: United States

Facility:
Name: Research Site

Address:
City: White Plains
Zip: 10601
Country: United States

Facility:
Name: Research Site

Address:
City: Houston
Zip: 77030
Country: United States

Facility:
Name: Research Site

Address:
City: Fort Belvoir
Zip: 22060
Country: United States

Facility:
Name: Research Site

Address:
City: Buenos Aires
Zip: C1431FWO
Country: Argentina

Facility:
Name: Research Site

Address:
City: Caba
Zip: C1012AAR
Country: Argentina

Facility:
Name: Research Site

Address:
City: Cipolletti
Zip: 8234
Country: Argentina

Facility:
Name: Research Site

Address:
City: La Plata
Zip: 1900
Country: Argentina

Facility:
Name: Research Site

Address:
City: Rosario
Zip: 2000
Country: Argentina

Facility:
Name: Research Site

Address:
City: Rosario
Zip: S2000CVB
Country: Argentina

Facility:
Name: Research Site

Address:
City: S.C. De Bariloche
Zip: 8400
Country: Argentina

Facility:
Name: Research Site

Address:
City: Barretos
Zip: 14784-400
Country: Brazil

Facility:
Name: Research Site

Address:
City: Belo Horizonte
Zip: 30380-090
Country: Brazil

Facility:
Name: Research Site

Address:
City: Porto Alegre
Zip: 90610-000
Country: Brazil

Facility:
Name: Research Site

Address:
City: Recife
Zip: 52010-075
Country: Brazil

Facility:
Name: Research Site

Address:
City: Rio de Janeiro
Zip: 22271-110
Country: Brazil

Facility:
Name: Research Site

Address:
City: Sao Paulo
Zip: 01327-001
Country: Brazil

Facility:
Name: Research Site

Address:
City: São Paulo
Zip: 04501-000
Country: Brazil

Facility:
Name: Research Site

Address:
City: Vancouver
Zip: V5Z 1M9
Country: Canada

Facility:
Name: Research Site

Address:
City: Montreal
Zip: H4A 3J1
Country: Canada

Facility:
Name: Research Site

Address:
City: Toronto
Zip: M5G 2M9
Country: Canada

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 100005
Country: China

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 100029
Country: China

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 100142
Country: China

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 100210
Country: China

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 100730
Country: China

Facility:
Name: Research Site

Address:
City: Beijing
Zip: 102218
Country: China

Facility:
Name: Research Site

Address:
City: Changchun
Zip: 130012
Country: China

Facility:
Name: Research Site

Address:
City: Changsha
Zip: 410013
Country: China

Facility:
Name: Research Site

Address:
City: Changsha
Zip: 430033
Country: China

Facility:
Name: Research Site

Address:
City: Chengdu
Zip: 610000
Country: China

Facility:
Name: Research Site

Address:
City: Fuzhou
Zip: 350014
Country: China

Facility:
Name: Research Site

Address:
City: Guangzhou
Zip: 510060
Country: China

Facility:
Name: Research Site

Address:
City: Guangzhou
Zip: 510100
Country: China

Facility:
Name: Research Site

Address:
City: Hangzhou
Zip: 310022
Country: China

Facility:
Name: Research Site

Address:
City: Harbin
Zip: 150049
Country: China

Facility:
Name: Research Site

Address:
City: Jinan
Zip: 250117
Country: China

Facility:
Name: Research Site

Address:
City: Nanjing
Zip: 210029
Country: China

Facility:
Name: Research Site

Address:
City: Shanghai
Zip: 200030
Country: China

Facility:
Name: Research Site

Address:
City: Shanghai
Zip: 200032
Country: China

Facility:
Name: Research Site

Address:
City: Shenzhen
Zip: 518116
Country: China

Facility:
Name: Research Site

Address:
City: Suzhou
Zip: 215006
Country: China

Facility:
Name: Research Site

Address:
City: Taiyuan
Zip: 030000
Country: China

Facility:
Name: Research Site

Address:
City: Xi'an
Zip: 710061
Country: China

Facility:
Name: Research Site

Address:
City: Xintai
Zip: 54031
Country: China

Facility:
Name: Research Site

Address:
City: Yangzhou
Zip: 225001
Country: China

Facility:
Name: Research Site

Address:
City: Zhengzhou
Zip: 450008
Country: China

Facility:
Name: Research Site

Address:
City: Berlin
Zip: 13125
Country: Germany

Facility:
Name: Research Site

Address:
City: Esslingen
Zip: 73730
Country: Germany

Facility:
Name: Research Site

Address:
City: Georgsmarienhuette
Zip: 49124
Country: Germany

Facility:
Name: Research Site

Address:
City: Lübeck
Zip: 23538
Country: Germany

Facility:
Name: Research Site

Address:
City: München
Zip: 81377
Country: Germany

Facility:
Name: Research Site

Address:
City: Würzburg
Zip: 97067
Country: Germany

Facility:
Name: Research Site

Address:
City: Bari
Zip: 70124
Country: Italy

Facility:
Name: Research Site

Address:
City: Catania
Zip: 95100
Country: Italy

Facility:
Name: Research Site

Address:
City: Firenze
Zip: 50134
Country: Italy

Facility:
Name: Research Site

Address:
City: Genova
Zip: 16132
Country: Italy

Facility:
Name: Research Site

Address:
City: Milan
Zip: 20141
Country: Italy

Facility:
Name: Research Site

Address:
City: Napoli
Zip: 80131
Country: Italy

Facility:
Name: Research Site

Address:
City: Padova
Zip: 35128
Country: Italy

Facility:
Name: Research Site

Address:
City: Parma
Zip: 43100
Country: Italy

Facility:
Name: Research Site

Address:
City: Roma
Zip: 00144
Country: Italy

Facility:
Name: Research Site

Address:
City: Torino
Zip: 10122
Country: Italy

Facility:
Name: Research Site

Address:
City: Chiba-shi
Zip: 260-0877
Country: Japan

Facility:
Name: Research Site

Address:
City: Fukuoka-shi
Zip: 812-8582
Country: Japan

Facility:
Name: Research Site

Address:
City: Hiroshima-shi
Zip: 734-8551
Country: Japan

Facility:
Name: Research Site

Address:
City: Kashiwa
Zip: 227-8577
Country: Japan

Facility:
Name: Research Site

Address:
City: Koto-ku
Zip: 135-8550
Country: Japan

Facility:
Name: Research Site

Address:
City: Kyoto-shi
Zip: 606-8507
Country: Japan

Facility:
Name: Research Site

Address:
City: Niigata-shi
Zip: 951-8566
Country: Japan

Facility:
Name: Research Site

Address:
City: Osaka-shi
Zip: 541-8567
Country: Japan

Facility:
Name: Research Site

Address:
City: Osakasayama-shi
Zip: 589-8511
Country: Japan

Facility:
Name: Research Site

Address:
City: Sendai-shi
Zip: 981-0914
Country: Japan

Facility:
Name: Research Site

Address:
City: Shinjuku-ku
Zip: 160-0023
Country: Japan

Facility:
Name: Research Site

Address:
City: Sunto-gun
Zip: 411-8777
Country: Japan

Facility:
Name: Research Site

Address:
City: Wakayama-shi
Zip: 641-8510
Country: Japan

Facility:
Name: Research Site

Address:
City: Daegu
Zip: 42415
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Jinju-si
Zip: 52727
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Seoul
Zip: 03082
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Seoul
Zip: 05505
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Seoul
Zip: 07061
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Suwon
Zip: 16247
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Suwon
Zip: 16499
Country: Korea, Republic of

Facility:
Name: Research Site

Address:
City: Kuala Lumpur
Zip: 59100
Country: Malaysia

Facility:
Name: Research Site

Address:
City: Kuching
Zip: 93586
Country: Malaysia

Facility:
Name: Research Site

Address:
City: Pulau Pinang
Zip: 10450
Country: Malaysia

Facility:
Name: Research Site

Address:
City: Selangor
Zip: 46050
Country: Malaysia

Facility:
Name: Research Site

Address:
City: Lublin
Zip: 20-090
Country: Poland

Facility:
Name: Research Site

Address:
City: Poznań
Zip: 60-569
Country: Poland

Facility:
Name: Research Site

Address:
City: Warszawa
Zip: 01-138
Country: Poland

Facility:
Name: Research Site

Address:
City: Bucharest
Zip: 050098
Country: Romania

Facility:
Name: Research Site

Address:
City: Bucuresti
Zip: 022328
Country: Romania

Facility:
Name: Research Site

Address:
City: Perm
Zip: 614990
Country: Russian Federation

Facility:
Name: Research Site

Address:
City: Saint Petersburg
Zip: 191036
Country: Russian Federation

Facility:
Name: Research Site

Address:
City: Singapore
Zip: 169610
Country: Singapore

Facility:
Name: Research Site

Address:
City: Singapore
Zip: 308433
Country: Singapore

Facility:
Name: Research Site

Address:
City: Barcelona
Zip: 08041
Country: Spain

Facility:
Name: Research Site

Address:
City: Málaga
Zip: 29010
Country: Spain

Facility:
Name: Research Site

Address:
City: Valencia
Zip: 46010
Country: Spain

Facility:
Name: Research Site

Address:
City: Vigo
Zip: 36312
Country: Spain

Facility:
Name: Research Site

Address:
City: Zaragoza
Zip: 50009
Country: Spain

Facility:
Name: Research Site

Address:
City: Taichung
Zip: 40201
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taichung
Zip: 40705
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Tainan
Zip: 70403
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taipei City
Zip: 114
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taipei
Zip: 100
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taipei
Zip: 11217
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taipei
Zip: 235
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Taoyuan
Zip: 333
Country: Taiwan

Facility:
Name: Research Site

Address:
City: Bangkok
Zip: 10300
Country: Thailand

Facility:
Name: Research Site

Address:
City: Bangkok
Zip: 10330
Country: Thailand

Facility:
Name: Research Site

Address:
City: Bangkok
Zip: 10700
Country: Thailand

Facility:
Name: Research Site

Address:
City: Hat Yai
Zip: 90110
Country: Thailand

Facility:
Name: Research Site

Address:
City: Khon Kaen
Zip: 40002
Country: Thailand

Facility:
Name: Research Site

Address:
City: Muang
Zip: 50200
Country: Thailand

Facility:
Name: Research Site

Address:
City: Ankara
Zip: 06010
Country: Turkey

Facility:
Name: Research Site

Address:
City: Bursa
Zip: 16059
Country: Turkey

Facility:
Name: Research Site

Address:
City: Istanbul
Country: Turkey

Facility:
Name: Research Site

Address:
City: Izmir
Zip: 35040
Country: Turkey

Facility:
Name: Research Site

Address:
City: Kadıkoy/Istanbul
Zip: 34722
Country: Turkey

Facility:
Name: Research Site

Address:
City: Birmingham
Zip: B9 5SS
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: Blackpool
Zip: FY3 8NR
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: London
Zip: SE1 9RT
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: London
Zip: SW10 9NH
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: London
Zip: SW3 6NP
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: Nottingham
Zip: NG5 1PB
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: Wythenshawe
Zip: M23 9LT
Country: United Kingdom

Facility:
Name: Research Site

Address:
City: Hanoi
Zip: 100000
Country: Vietnam

Facility:
Name: Research Site

Address:
City: Ho Chi Minh city
Zip: 700000
Country: Vietnam

Facility:
Name: Research Site

Address:
City: Ho Chi Minh
Zip: 700000
Country: Vietnam

Start date: February 21, 2022

Completion date: November 1, 2032

Lead sponsor:
Agency: AstraZeneca
Agency class: Industry

Source: AstraZeneca

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05120349
https://www.lungcancerstudylocator.com/trial/listing/310876